United States - English - NLM (National Library of Medicine)

ucb, inc. - rotigotine (unii: 87t4t8bo2e) (rotigotine - unii:87t4t8bo2e) - rotigotine 1 mg in 24 h - neupro is indicated for the treatment of parkinson's disease. neupro is indicated for the treatment of moderate-to-severe primary restless legs syndrome. neupro is contraindicated in patients who have demonstrated hypersensitivity to rotigotine or the components of the transdermal system. risk summary there are no adequate data on the developmental risk associated with the use of neupro in pregnant women. in animal studies, rotigotine was shown to have adverse effects on embryofetal development when administered during pregnancy at doses similar to or lower than those used clinically [see data ]. in the u.s. general population, the estimated background risk of major birth defects and of miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. the background risk of major birth defects and miscarriage in the indicated population is unknown. data animal data rotigotine administered subcutaneously (0, 10, 30, or 90 mg/kg/day) to pregnant mice during organogenesis (gestation days

Australia - English - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - rotigotine, quantity: 18 mg - drug delivery system, transdermal - excipient ingredients: povidone; ascorbyl palmitate; dl-alpha-tocopherol; sodium metabisulfite; methylated trimethylated silica; heptane - parkinson's disease: neupro is indicated as monotherapy, or in combination with levodopa, for the treatment of idiopathic parkinson's disease from early stage to advanced disease. restless legs syndrome: neupro is indicated for the symptomatic treatment of moderate to severe idiopathic restless legs syndrome in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - rotigotine, quantity: 13.5 mg - drug delivery system, transdermal - excipient ingredients: ascorbyl palmitate; povidone; dl-alpha-tocopherol; sodium metabisulfite; methylated trimethylated silica; heptane - parkinson's disease: neupro is indicated as monotherapy, or in combination with levodopa, for the treatment of idiopathic parkinson's disease from early stage to advanced disease. restless legs syndrome: neupro is indicated for the symptomatic treatment of moderate to severe idiopathic restless legs syndrome in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - rotigotine, quantity: 9 mg - drug delivery system, transdermal - excipient ingredients: ascorbyl palmitate; povidone; dl-alpha-tocopherol; sodium metabisulfite; methylated trimethylated silica; heptane - parkinson's disease: neupro is indicated as monotherapy, or in combination with levodopa, for the treatment of idiopathic parkinson's disease from early stage to advanced disease. restless legs syndrome: neupro is indicated for the symptomatic treatment of moderate to severe idiopathic restless legs syndrome in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - rotigotine, quantity: 4.5 mg - drug delivery system, transdermal - excipient ingredients: dl-alpha-tocopherol; ascorbyl palmitate; povidone; sodium metabisulfite; methylated trimethylated silica; heptane - parkinson's disease: neupro is indicated as monotherapy, or in combination with levodopa, for the treatment of idiopathic parkinson's disease from early stage to advanced disease. restless legs syndrome: neupro is indicated for the symptomatic treatment of moderate to severe idiopathic restless legs syndrome in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - rotigotine, quantity: 6.75 mg - drug delivery system, transdermal - excipient ingredients: povidone; dl-alpha-tocopherol; sodium metabisulfite; ascorbyl palmitate; methylated trimethylated silica; heptane - parkinson's disease, neupro is indicated as monotherapy, or in combination with levodopa, for the treatment of idiopathic parkinson's disease from early stage to advanced disease. restless legs syndrome, neupro is indicated for the symptomatic treatment of moderate to severe idiopathic restless legs syndrome in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - rotigotine, quantity: 2.25 mg - drug delivery system, transdermal - excipient ingredients: dl-alpha-tocopherol; povidone; ascorbyl palmitate; sodium metabisulfite; methylated trimethylated silica; heptane - parkinson's disease, neupro is indicated as monotherapy, or in combination with levodopa, for the treatment of idiopathic parkinson's disease from early stage to advanced disease. restless legs syndrome, neupro is indicated for the symptomatic treatment of moderate to severe idiopathic restless legs syndrome in adults.

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - rotigotine 4.5mg; rotigotine 4.5mg - transdermal patch - 2 mg/24h - active: rotigotine 4.5mg excipient: ascorbyl palmitate dl-alpha tocopherol silicone adhesive bio-psa q7-4301 silicone adhesive bio-psa q7-4201 povidone sodium metabisulfite active: rotigotine 4.5mg excipient: ascorbyl palmitate dl-alpha tocopherol silicone adhesive bio-psa q7-4301 silicone adhesive bio-psa q7-4201 povidone sodium metabisulfite - neupro is indicated as monotherapy, or in combination with levodopa, for the treatment of idiopathic parkinson's disease from early stage to advanced disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - rotigotine 9mg; rotigotine 9mg - transdermal patch - 4 mg/24h - active: rotigotine 9mg excipient: ascorbyl palmitate dl-alpha tocopherol silicone adhesive bio-psa q7-4301 silicone adhesive bio-psa q7-4201 povidone sodium metabisulfite active: rotigotine 9mg excipient: ascorbyl palmitate dl-alpha tocopherol silicone adhesive bio-psa q7-4301 silicone adhesive bio-psa q7-4201 povidone sodium metabisulfite - neupro is indicated as monotherapy, or in combination with levodopa, for the treatment of idiopathic parkinson's disease from early stage to advanced disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - rotigotine 13.5mg; rotigotine 13.5mg - transdermal patch - 6 mg/24h - active: rotigotine 13.5mg excipient: ascorbyl palmitate dl-alpha tocopherol silicone adhesive bio-psa q7-4301 silicone adhesive bio-psa q7-4201 povidone sodium metabisulfite active: rotigotine 13.5mg excipient: ascorbyl palmitate dl-alpha tocopherol silicone adhesive bio-psa q7-4301 silicone adhesive bio-psa q7-4201 povidone sodium metabisulfite - neupro is indicated as monotherapy, or in combination with levodopa, for the treatment of idiopathic parkinson's disease from early stage to advanced disease.